JP2014040441A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014040441A5 JP2014040441A5 JP2013201931A JP2013201931A JP2014040441A5 JP 2014040441 A5 JP2014040441 A5 JP 2014040441A5 JP 2013201931 A JP2013201931 A JP 2013201931A JP 2013201931 A JP2013201931 A JP 2013201931A JP 2014040441 A5 JP2014040441 A5 JP 2014040441A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- peptibody
- buffer
- composition
- mannitol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US79399706P | 2006-04-21 | 2006-04-21 | |
| US60/793,997 | 2006-04-21 | ||
| US11/788,697 | 2007-04-19 | ||
| US11/788,697 US9283260B2 (en) | 2006-04-21 | 2007-04-19 | Lyophilized therapeutic peptibody formulations |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009506615A Division JP5432705B2 (ja) | 2006-04-21 | 2007-04-20 | 凍結乾燥された治療用ペプチボディ製剤 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015208065A Division JP6356106B2 (ja) | 2006-04-21 | 2015-10-22 | 凍結乾燥された治療用ペプチボディ製剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014040441A JP2014040441A (ja) | 2014-03-06 |
| JP2014040441A5 true JP2014040441A5 (enExample) | 2014-06-19 |
| JP5873854B2 JP5873854B2 (ja) | 2016-03-01 |
Family
ID=38625630
Family Applications (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009506615A Active JP5432705B2 (ja) | 2006-04-21 | 2007-04-20 | 凍結乾燥された治療用ペプチボディ製剤 |
| JP2013201931A Active JP5873854B2 (ja) | 2006-04-21 | 2013-09-27 | 凍結乾燥された治療用ペプチボディ製剤 |
| JP2015208065A Active JP6356106B2 (ja) | 2006-04-21 | 2015-10-22 | 凍結乾燥された治療用ペプチボディ製剤 |
| JP2018111720A Active JP6787953B2 (ja) | 2006-04-21 | 2018-06-12 | 凍結乾燥された治療用ペプチボディ製剤 |
| JP2020128961A Pending JP2021006525A (ja) | 2006-04-21 | 2020-07-30 | 凍結乾燥された治療用ペプチボディ製剤 |
| JP2022130437A Pending JP2022166219A (ja) | 2006-04-21 | 2022-08-18 | 凍結乾燥された治療用ペプチボディ製剤 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009506615A Active JP5432705B2 (ja) | 2006-04-21 | 2007-04-20 | 凍結乾燥された治療用ペプチボディ製剤 |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015208065A Active JP6356106B2 (ja) | 2006-04-21 | 2015-10-22 | 凍結乾燥された治療用ペプチボディ製剤 |
| JP2018111720A Active JP6787953B2 (ja) | 2006-04-21 | 2018-06-12 | 凍結乾燥された治療用ペプチボディ製剤 |
| JP2020128961A Pending JP2021006525A (ja) | 2006-04-21 | 2020-07-30 | 凍結乾燥された治療用ペプチボディ製剤 |
| JP2022130437A Pending JP2022166219A (ja) | 2006-04-21 | 2022-08-18 | 凍結乾燥された治療用ペプチボディ製剤 |
Country Status (38)
Families Citing this family (87)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HK1042114B (zh) | 1998-10-23 | 2006-09-29 | Amgen K-A, Inc. | 与mp1受体结合并具有血小板生成活性的模拟二聚体血小板生成素肽 |
| CA2634663C (en) | 1999-02-22 | 2009-08-25 | University Of Connecticut | Novel albumin-free factor viii formulations |
| US7658938B2 (en) | 1999-02-22 | 2010-02-09 | Merrion Reasearch III Limited | Solid oral dosage form containing an enhancer |
| HK1043320A1 (zh) | 1999-06-01 | 2002-09-13 | Biogen, Inc. | Vla-1的一种阻塞性单系抗体，以及其治疗炎性失调的功用 |
| UA83791C2 (ru) | 2001-04-13 | 2008-08-26 | Байоджен Айдек Ма Инк. | Антитело против vla-1, фармацевтическая композиция, которая его содержит, и из применение для лечения индивидуума с иммунологическим расстройством, опосредованным vla-1 |
| CA2822302A1 (en) | 2006-02-13 | 2007-08-23 | Alethia Biotherapeutics Inc. | Methods of impairing osteoclast differentiation |
| US8168181B2 (en) | 2006-02-13 | 2012-05-01 | Alethia Biotherapeutics, Inc. | Methods of impairing osteoclast differentiation using antibodies that bind siglec-15 |
| WO2007117706A2 (en) | 2006-04-07 | 2007-10-18 | Merrion Research Iii Limited | Solid oral dosage form containing an enhancer |
| AU2011265555B2 (en) * | 2006-04-21 | 2016-03-10 | Amgen Inc. | Lyophilized therapeutic peptibody formulations |
| US9283260B2 (en) * | 2006-04-21 | 2016-03-15 | Amgen Inc. | Lyophilized therapeutic peptibody formulations |
| BRPI0712607A8 (pt) | 2006-05-25 | 2019-06-04 | Biogen Idec Inc | métodos de tratamento de acidente vascular cerebral |
| CN102046192B (zh) | 2008-05-07 | 2014-11-19 | 默里昂研究Ⅲ有限公司 | GnRH相关化合物的组合物及制备方法 |
| EP2385825B1 (en) * | 2008-11-07 | 2018-10-10 | University of Connecticut | Factor viii formulations |
| PL2889043T3 (pl) * | 2008-12-16 | 2019-09-30 | Genzyme Corporation | Syntetyczne związki pośrednie do wytwarzania koniugatów oligosacharyd-białko |
| US20120183546A1 (en) | 2009-09-23 | 2012-07-19 | Amgen Inc. | Treatment of ovarian cancer using a specific binding agent of human angiopoietin-2 in combination with a taxane |
| US8829163B2 (en) * | 2010-01-19 | 2014-09-09 | Hanmi Science Co., Ltd | Liquid formulations for long-acting erythropoietin conjugate |
| WO2011120033A1 (en) | 2010-03-26 | 2011-09-29 | Merrion Research Iii Limited | Pharmaceutical compositions of selective factor xa inhibitors for oral administration |
| CN103269716B (zh) | 2010-12-02 | 2015-05-27 | 昂科利蒂克斯生物科技公司 | 冻干病毒制剂 |
| WO2012075379A2 (en) | 2010-12-02 | 2012-06-07 | Oncolytics Biotech Inc. | Liquid viral formulations |
| JP5759211B2 (ja) * | 2011-03-11 | 2015-08-05 | 三洋化成工業株式会社 | 凍結乾燥方法 |
| MX358726B (es) | 2011-06-29 | 2018-09-03 | Amgen Inc | Biomarcador predictivo de supervivencia en el tratamiento de carcinoma de celulas renales. |
| DE102011055889B4 (de) * | 2011-11-30 | 2013-08-01 | Otc Gmbh | Verfahren zur Herstellung eines Protein-Hydrolysates |
| CN102586217A (zh) * | 2011-12-16 | 2012-07-18 | 深圳市海普瑞药业股份有限公司 | 肝素黄杆菌肝素酶ⅰ、ⅱ、ⅲ的冻干保存方法 |
| RU2482128C1 (ru) * | 2011-12-28 | 2013-05-20 | Замертон Холдингс Лимитед | Пептиды, обладающие цитопротекторной активностью |
| ES2732243T3 (es) * | 2012-02-16 | 2019-11-21 | Santarus Inc | Composiciones farmacéuticas de anticuerpos ANTI-VLA1 (CD49A) |
| EP2644186A1 (en) * | 2012-03-26 | 2013-10-02 | OTC GmbH | Hair conditioning composition for permanent and semi-permanent hair coloration applications |
| JP2015525748A (ja) * | 2012-06-25 | 2015-09-07 | エマージェント プロダクト デベロップメント ゲイザーズバーグ インコーポレイテッド | 温度に安定なワクチン製剤 |
| ES2723885T3 (es) | 2012-07-19 | 2019-09-03 | Daiichi Sankyo Co Ltd | Anticuerpos anti-Siglec-15 |
| EP2698162A1 (en) | 2012-08-15 | 2014-02-19 | Credentis AG | Method for producing a composition for treating a tooth lesion |
| US20160038588A1 (en) * | 2013-03-15 | 2016-02-11 | Amgen Inc. | Myostatin Antagonism in Human Subjects |
| CN104274827B (zh) * | 2013-07-01 | 2020-07-14 | 上海贺普药业股份有限公司 | 贺普拉肽的制剂 |
| WO2015035405A1 (en) * | 2013-09-09 | 2015-03-12 | Pinta Biotherapeutics, Inc. | Myostatin antagonist for treatment of pew in esrd patients |
| TR201902755T4 (tr) * | 2013-11-07 | 2019-03-21 | Dr August Wolff Gmbh & Co Kg Arzneimittel | Depolama kararliliğina sahi̇p li̇yofi̇li̇ze tri̇pepti̇t formülasyonlari. |
| US10801070B2 (en) | 2013-11-25 | 2020-10-13 | The Broad Institute, Inc. | Compositions and methods for diagnosing, evaluating and treating cancer |
| US11725237B2 (en) | 2013-12-05 | 2023-08-15 | The Broad Institute Inc. | Polymorphic gene typing and somatic change detection using sequencing data |
| JP6740127B2 (ja) * | 2013-12-06 | 2020-08-12 | ザ・ブロード・インスティテュート・インコーポレイテッド | 新生物ワクチン用製剤 |
| NZ721908A (en) | 2013-12-20 | 2022-12-23 | Massachusetts Gen Hospital | Combination therapy with neoantigen vaccine |
| US10357559B2 (en) | 2013-12-27 | 2019-07-23 | Emergent Product Development Gaithersburg Inc. | Temperature stable vaccine formulations |
| SG11201605242YA (en) | 2014-01-10 | 2016-07-28 | Biogen Ma Inc | Factor viii chimeric proteins and uses thereof |
| US11299528B2 (en) | 2014-03-11 | 2022-04-12 | D&D Pharmatech Inc. | Long acting TRAIL receptor agonists for treatment of autoimmune diseases |
| EP3125923B1 (en) * | 2014-03-29 | 2024-10-16 | Intas Pharmaceuticals Limited | Lyophilized pharmaceutical composition of fc-peptide fusion protein |
| SMT202000307T1 (it) * | 2014-05-28 | 2020-07-08 | Nono Inc | Sale cloruro di tat-nr2b9c |
| PE20170471A1 (es) * | 2014-06-13 | 2017-05-14 | Santa Maria Biotherapeutics Inc | Polipeptidos receptores formulados y metodos relacionados |
| EA202091385A3 (ru) * | 2014-08-20 | 2021-06-30 | Портола Фармасьютикалз, Инк. | Лиофилизированные составы для антидота фактора ха |
| JP6671141B2 (ja) * | 2014-10-21 | 2020-03-25 | 大日本住友製薬株式会社 | 懸濁液剤 |
| US10975442B2 (en) | 2014-12-19 | 2021-04-13 | Massachusetts Institute Of Technology | Molecular biomarkers for cancer immunotherapy |
| EP4636401A2 (en) | 2014-12-19 | 2025-10-22 | The Broad Institute, Inc. | Methods for profiling the t-cell-receptor repertoire |
| US10265384B2 (en) | 2015-01-29 | 2019-04-23 | Novo Nordisk A/S | Tablets comprising GLP-1 agonist and enteric coating |
| WO2016176427A1 (en) | 2015-04-30 | 2016-11-03 | Amgen Inc. | Treatment of ovarian cancer in patients with ascites using a specific binding agent of human angiopoietin-2 in combination with a taxane |
| CA2986235A1 (en) | 2015-05-20 | 2016-11-24 | The Broad Institute, Inc. | Shared neoantigens |
| US11007251B2 (en) | 2015-12-17 | 2021-05-18 | The Johns Hopkins University | Ameliorating systemic sclerosis with death receptor agonists |
| AU2017205690B2 (en) | 2016-01-08 | 2022-04-28 | Ascendis Pharma Growth Disorders A/S | Controlled-release CNP agonists with increased NEP stability |
| NZ743488A (en) | 2016-01-08 | 2023-02-24 | Ascendis Pharma Growth Disorders As | Controlled-release cnp agonists with low initial npr-b activity |
| CA3008017C (en) | 2016-01-08 | 2024-01-02 | Ascendis Pharma Growth Disorders A/S | Controlled-release cnp agonists with reduced side-effects |
| AU2017205688C1 (en) | 2016-01-08 | 2022-03-10 | Ascendis Pharma Growth Disorders A/S | Cnp prodrugs with carrier attachment at the ring moiety |
| JP6992262B2 (ja) * | 2016-03-31 | 2022-02-15 | 東ソー株式会社 | 変性抗体測定試薬の製造方法 |
| AU2017248264B2 (en) | 2016-04-07 | 2020-01-30 | The Johns Hopkins University | Compositions and methods for treating pancreatitis and pain with death receptor agonists |
| GB201608323D0 (en) | 2016-05-12 | 2016-06-29 | Ucb Biopharma Sprl | Pharmaceutical compositions |
| WO2017197199A1 (en) * | 2016-05-13 | 2017-11-16 | Askgene Pharma Inc. | Novel angiopoietin 2, vegf dual antagonists |
| MX2019006444A (es) | 2016-12-02 | 2019-10-30 | Bioverativ Therapeutics Inc | Métodos de tratamiento de artropatía hemofílica utilizando factores de coagulación quiméricos. |
| US11549149B2 (en) | 2017-01-24 | 2023-01-10 | The Broad Institute, Inc. | Compositions and methods for detecting a mutant variant of a polynucleotide |
| JP2017155046A (ja) * | 2017-04-05 | 2017-09-07 | イーストポンド・ラボラトリーズ・リミテッド | シクロデキストリンを含有する細胞水和組成物 |
| KR20250093620A (ko) | 2017-09-15 | 2025-06-24 | 암젠 인크 | 치료 단백질의 동결건조된 약학적 제형을 위한 방법 |
| EP3684332A1 (en) * | 2017-09-18 | 2020-07-29 | Amgen Inc. | Vegfr-fc fusion protein formulations |
| EP3730126B1 (en) * | 2017-12-22 | 2025-05-14 | Samsung Bioepis Co., Ltd. | Liquid composition comprising vegf antagonist |
| CN108159413B (zh) * | 2018-01-10 | 2021-07-06 | 杭州洪桥中科基因技术有限公司 | 一种动物用冻干活疫苗及其制备方法 |
| GB201804835D0 (en) * | 2018-03-26 | 2018-05-09 | Ge Healthcare As | Formulation and method of preparation |
| SI3793588T1 (sl) | 2018-05-18 | 2025-07-31 | Bioverativ Therapeutics Inc. | Postopki zdravljenja hemofilije A |
| EP3829642A1 (en) * | 2018-07-31 | 2021-06-09 | Amgen Inc. | Pharmaceutical formulations of masked antibodies |
| EP3923906A1 (en) | 2019-02-11 | 2021-12-22 | Ascendis Pharma Growth Disorders A/S | Dry pharmaceutical formulations of cnp conjugates |
| SG11202108627SA (en) | 2019-02-18 | 2021-09-29 | Lilly Co Eli | Therapeutic antibody formulation |
| AU2020254582B2 (en) * | 2019-04-01 | 2025-12-18 | Genentech, Inc. | Compositions and methods for stabilizing protein-containing formulations |
| EP3736574A1 (en) * | 2019-05-07 | 2020-11-11 | Atlas Antibodies AB | A formulation comprising an isotope labeled fusion polypeptide |
| DK3744319T3 (da) | 2019-05-28 | 2023-01-16 | Ilkogen Ilac Sanayi Ve Ticaret A S | Stabil lyofiliseret formulering til hybrid fc-fusioneret g-csf |
| JP2019178154A (ja) * | 2019-06-18 | 2019-10-17 | イーストポンド・ラボラトリーズ・リミテッド | シクロデキストリンを含有する細胞水和組成物 |
| GB201911461D0 (en) * | 2019-08-09 | 2019-09-25 | Arecor Ltd | Novel composition |
| US20220409627A1 (en) * | 2019-12-02 | 2022-12-29 | Altavant Sciences Gmbh | Treatment of lower airways disorders |
| US20230026969A1 (en) * | 2019-12-03 | 2023-01-26 | China Medical University | Oligopeptide, Testing Kit Thereof And Medical Composition Thereof |
| KR102844733B1 (ko) | 2019-12-10 | 2025-08-11 | 레메젠 코, 리미티드 | 약제학적 TACI-Fc 융합 단백질 제제 |
| US11767353B2 (en) | 2020-06-05 | 2023-09-26 | Theraly Fibrosis, Inc. | Trail compositions with reduced immunogenicity |
| PL4200319T3 (pl) * | 2020-08-21 | 2025-08-18 | Resother Pharma A/S | Preparaty peptydu n-końcowego aneksyny a1 i sposoby |
| CN117255809B (zh) * | 2021-03-31 | 2025-05-30 | 杭州嘉因生物科技有限公司 | 靶向vegf和血管生成素的融合分子及其用途 |
| CA3239280A1 (en) | 2021-12-01 | 2023-06-08 | UCB Biopharma SRL | Formulations comprising fab-peg |
| US20240076597A1 (en) * | 2022-09-02 | 2024-03-07 | Terumo Bct, Inc. | Methods for cell expansion, differentiation, and/or harvesting of natural killer cells using hollow-fiber membranes |
| WO2024133908A1 (en) * | 2022-12-23 | 2024-06-27 | Syna Therapeutics, S.L. | Stable pharmaceutical compositions comprising romiplostim |
| AU2024314758A1 (en) * | 2023-06-23 | 2026-01-22 | The Regents Of The University Of Michigan | Nanoparticle compositions associated with peptides |
| CN117186173B (zh) * | 2023-09-14 | 2024-04-05 | 海南大学 | 抑制Aβ42聚集并降低其细胞毒作用的三肽化合物 |
Family Cites Families (110)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3691016A (en) | 1970-04-17 | 1972-09-12 | Monsanto Co | Process for the preparation of insoluble enzymes |
| CA1023287A (en) | 1972-12-08 | 1977-12-27 | Boehringer Mannheim G.M.B.H. | Process for the preparation of carrier-bound proteins |
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| US3941763A (en) | 1975-03-28 | 1976-03-02 | American Home Products Corporation | PGlu-D-Met-Trp-Ser-Tyr-D-Ala-Leu-Arg-Pro-Gly-NH2 and intermediates |
| US4002531A (en) | 1976-01-22 | 1977-01-11 | Pierce Chemical Company | Modifying enzymes with polyethylene glycol and product produced thereby |
| US4195128A (en) | 1976-05-03 | 1980-03-25 | Bayer Aktiengesellschaft | Polymeric carrier bound ligands |
| US4330440A (en) | 1977-02-08 | 1982-05-18 | Development Finance Corporation Of New Zealand | Activated matrix and method of activation |
| CA1093991A (en) | 1977-02-17 | 1981-01-20 | Hideo Hirohara | Enzyme immobilization with pullulan gel |
| US4229537A (en) | 1978-02-09 | 1980-10-21 | New York University | Preparation of trichloro-s-triazine activated supports for coupling ligands |
| DE3244265A1 (de) | 1982-11-30 | 1984-05-30 | Cassella Ag, 6000 Frankfurt | Weichmacheremulsion, verfahren zu ihrer herstellung und ihre anwendung |
| US4503235A (en) | 1983-03-11 | 1985-03-05 | Warner-Lambert Company | Process for producing 4-carbamoyl-1H-imidazolium-5-olate |
| EP0154316B1 (en) | 1984-03-06 | 1989-09-13 | Takeda Chemical Industries, Ltd. | Chemically modified lymphokine and production thereof |
| DE3889853D1 (de) | 1987-11-05 | 1994-07-07 | Hybritech Inc | Polysaccharidmodifizierte Immunglobuline mit reduziertem immunogenem Potential oder verbesserter Pharmakokinetik. |
| US4904584A (en) | 1987-12-23 | 1990-02-27 | Genetics Institute, Inc. | Site-specific homogeneous modification of polypeptides |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| GB8824591D0 (en) | 1988-10-20 | 1988-11-23 | Royal Free Hosp School Med | Fractionation process |
| WO1990006952A1 (fr) | 1988-12-22 | 1990-06-28 | Kirin-Amgen, Inc. | Facteur de stimulation de colonies de granulocytes modifies chimiquement |
| US4902502A (en) | 1989-01-23 | 1990-02-20 | Cetus Corporation | Preparation of a polymer/interleukin-2 conjugate |
| US5089261A (en) | 1989-01-23 | 1992-02-18 | Cetus Corporation | Preparation of a polymer/interleukin-2 conjugate |
| US5225538A (en) | 1989-02-23 | 1993-07-06 | Genentech, Inc. | Lymphocyte homing receptor/immunoglobulin fusion proteins |
| US5627262A (en) | 1989-07-05 | 1997-05-06 | The Board Of Regents Of The University Of Oklahoma | Method and composition for the treatment of septic shock |
| DE59010908D1 (de) | 1989-09-12 | 2000-08-10 | Hoffmann La Roche | TNF-bindende Proteine |
| JPH04218000A (ja) | 1990-02-13 | 1992-08-07 | Kirin Amgen Inc | 修飾ポリペプチド |
| US5723286A (en) | 1990-06-20 | 1998-03-03 | Affymax Technologies N.V. | Peptide library and screening systems |
| US5252714A (en) | 1990-11-28 | 1993-10-12 | The University Of Alabama In Huntsville | Preparation and use of polyethylene glycol propionaldehyde |
| GEP20033082B (en) | 1991-03-15 | 2003-10-27 | Amgen Inc | Pegylation of Polypeptides |
| US5595732A (en) | 1991-03-25 | 1997-01-21 | Hoffmann-La Roche Inc. | Polyethylene-protein conjugates |
| US5281698A (en) | 1991-07-23 | 1994-01-25 | Cetus Oncology Corporation | Preparation of an activated polymer ester for protein conjugation |
| US5362852A (en) | 1991-09-27 | 1994-11-08 | Pfizer Inc. | Modified peptide derivatives conjugated at 2-hydroxyethylamine moieties |
| US5270170A (en) | 1991-10-16 | 1993-12-14 | Affymax Technologies N.V. | Peptide library and screening method |
| US5733731A (en) | 1991-10-16 | 1998-03-31 | Affymax Technologies N.V. | Peptide library and screening method |
| NZ244778A (en) | 1991-10-21 | 1994-03-25 | Ortho Pharma Corp | Peg imidates and protein derivatives thereof |
| DK0615451T3 (da) | 1992-05-26 | 2006-04-24 | Immunex Corp | Hidtil ukendt cytokin der binder til CD30 |
| CA2142007C (en) | 1992-08-11 | 2007-10-30 | Robert Glen Urban | Immunomodulatory peptides |
| GB9225448D0 (en) | 1992-12-04 | 1993-01-27 | Erba Carlo Spa | Improved synthesis of polymer bioactive conjugates |
| US5922545A (en) | 1993-10-29 | 1999-07-13 | Affymax Technologies N.V. | In vitro peptide and antibody display libraries |
| US5773569A (en) | 1993-11-19 | 1998-06-30 | Affymax Technologies N.V. | Compounds and peptides that bind to the erythropoietin receptor |
| US5981478A (en) | 1993-11-24 | 1999-11-09 | La Jolla Cancer Research Foundation | Integrin-binding peptides |
| US5880096A (en) | 1994-02-02 | 1999-03-09 | Affymax Technologies N.V. | Peptides and compounds that bind to the IL-1 receptor |
| US5786331A (en) | 1994-02-02 | 1998-07-28 | Affymax Technologies N.V. | Peptides and compounds that bind to the IL-1 receptor |
| US5608035A (en) | 1994-02-02 | 1997-03-04 | Affymax Technologies N.V. | Peptides and compounds that bind to the IL-1 receptor |
| US5844929A (en) * | 1994-02-24 | 1998-12-01 | British Telecommunications Public Limited Company | Optical device with composite passive and tapered active waveguide regions |
| US6309853B1 (en) | 1994-08-17 | 2001-10-30 | The Rockfeller University | Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof |
| US20030053982A1 (en) | 1994-09-26 | 2003-03-20 | Kinstler Olaf B. | N-terminally chemically modified protein compositions and methods |
| US5824784A (en) | 1994-10-12 | 1998-10-20 | Amgen Inc. | N-terminally chemically modified protein compositions and methods |
| AU693478B2 (en) | 1994-11-10 | 1998-07-02 | Metabolic Pharmaceuticals Limited | Treatment of obesity |
| IL116026A (en) | 1994-11-22 | 2005-08-31 | Rhone Poulenc Rorer Sa | Peptides capable of linking to the sh3 domain of gap, nucleotide sequences encoding the same, their preparation and uses |
| US5888763A (en) | 1994-12-30 | 1999-03-30 | The Rockefeller University | Peptides specific for the first Crk-SH3 domain |
| JP2000510813A (ja) * | 1995-02-06 | 2000-08-22 | ジェネテイックス・インスティテュート・インコーポレイテッド | Ｉｌ−１２用処方 |
| IL113159A0 (en) | 1995-03-28 | 1995-06-29 | Yeda Res & Dev | Synthetic peptides and pharmaceutical compositions comprising them |
| US6096871A (en) | 1995-04-14 | 2000-08-01 | Genentech, Inc. | Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life |
| US5739277A (en) | 1995-04-14 | 1998-04-14 | Genentech Inc. | Altered polypeptides with increased half-life |
| US5767078A (en) | 1995-06-07 | 1998-06-16 | Johnson; Dana L. | Agonist peptide dimers |
| US5869451A (en) | 1995-06-07 | 1999-02-09 | Glaxo Group Limited | Peptides and compounds that bind to a receptor |
| CA2226575C (en) | 1995-07-27 | 2011-10-18 | Genentech, Inc. | Stabile isotonic lyophilized protein formulation |
| US5746516A (en) | 1995-08-11 | 1998-05-05 | Hitachi Powdered Metals Co., Ltd. | Porous bearing system having internal grooves and electric motor provided with the same |
| US5817750A (en) | 1995-08-28 | 1998-10-06 | La Jolla Cancer Research Foundation | Structural mimics of RGD-binding sites |
| JPH09151200A (ja) | 1995-09-29 | 1997-06-10 | Ajinomoto Co Inc | ヒト胃癌に対する免疫応答を誘導できるペプチド及び該ペプチドを含むヒト胃癌治療、予防剤 |
| US6369027B1 (en) | 1995-12-22 | 2002-04-09 | Amgen Inc. | Osteoprotegerin |
| US5714577A (en) | 1996-01-26 | 1998-02-03 | University Of Pittsburgh | Antimicrobial peptides |
| IL117223A0 (en) | 1996-02-22 | 1996-06-18 | Yeda Res & Dev | Antipathogenic polypeptides and compositions comprising them |
| ATE279947T1 (de) | 1996-03-18 | 2004-11-15 | Univ Texas | Immunglobulinähnliche domäne mit erhöhten halbwertszeiten |
| JP4088344B2 (ja) | 1996-03-28 | 2008-05-21 | カイロン コーポレイション | ウロキナーゼレセプターのペプチドリガンド |
| IL118003A0 (en) | 1996-04-23 | 1996-08-04 | Yeda Res & Dev | Novel vip fragments and pharmaceutical compositions comprising them |
| FR2748028B1 (fr) | 1996-04-30 | 1998-08-14 | Lab Francais Du Fractionnement | Peptides derives du facteur von willebrand et leur utilisation comme anticoagulant |
| WO1997046668A1 (en) | 1996-06-07 | 1997-12-11 | Takeda Chemical Industries, Ltd. | Novel peptide, process for the production of the same, and use of the same |
| US6126939A (en) | 1996-09-03 | 2000-10-03 | Yeda Research And Development Co. Ltd. | Anti-inflammatory dipeptide and pharmaceutical composition thereof |
| JP2001501600A (ja) | 1996-09-10 | 2001-02-06 | ザ バーナム インスティテュート | 腫瘍ホーミング分子、それに由来する結合体、およびその使用方法 |
| JP2001501619A (ja) * | 1996-10-04 | 2001-02-06 | アムジェン インコーポレーテッド | ｍｐｌリガンドを含有する医薬組成物 |
| JP2001512560A (ja) | 1996-10-08 | 2001-08-21 | ユー―ビスイス ベスローテン フェンノートシャップ | 標的に対し特異的な親和性を有するペプチドおよびタンパク質の選択のための方法および手段 |
| WO1998033812A1 (en) | 1997-02-05 | 1998-08-06 | Brigham And Women's Hospital, Inc. | Mast cell protease peptide inhibitors |
| SI0975754T2 (sl) | 1997-04-16 | 2016-04-29 | Amgen Inc., | Vezivni proteini in receptorji osteoprotegerina |
| US6265535B1 (en) | 1997-05-30 | 2001-07-24 | The Trustees Of The University Of Pennsylvania | Peptides and peptide analogues designed from binding sites of tumor necrosis factor receptor superfamily and their uses |
| US6171586B1 (en) | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
| JP2001522863A (ja) | 1997-11-07 | 2001-11-20 | コンジュケム，インコーポレーテッド | Ｒｇｄ含有ペプチドおよび内因性担体の新規コンジュゲート |
| AU2481399A (en) | 1998-01-29 | 1999-08-16 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Variant peptide ligands that selectively induce apoptosis |
| DE69921102T2 (de) | 1998-03-05 | 2006-02-02 | Chiron Corp., Emeryville | Verfahren zur verbesserung der serum-halbwertszeit von biologisch aktiven molekülen |
| US6235872B1 (en) | 1998-03-12 | 2001-05-22 | The Burnham Institute | Proapoptotic peptides dependence polypeptides and methods of use |
| JP4361684B2 (ja) | 1998-03-20 | 2009-11-11 | 中外製薬株式会社 | エリトロポエチン受容体のためのペプチドリガンド |
| EP0947524A1 (en) | 1998-03-30 | 1999-10-06 | Upither B.V. | Novel peptides for the treatment of autoimmune diseases |
| JP2002510641A (ja) | 1998-04-06 | 2002-04-09 | アドヴァンスト・イミューニット・インク | 神経退化疾患治療用短ペプチド |
| ATE399567T1 (de) | 1998-04-28 | 2008-07-15 | Serono Lab | Peg konjugate von lhrh analogen |
| EP0972780A1 (en) | 1998-05-18 | 2000-01-19 | Applied Research Systems ARS Holding N.V. | Il-6 antagonist peptides |
| JP3753612B2 (ja) | 1998-05-22 | 2006-03-08 | アボット・ラボラトリーズ | 抗血管新生作用を有するペプチド医薬 |
| US5932548A (en) | 1998-06-03 | 1999-08-03 | Deghenghi; Romano | Lysine containing peptides for treatment of heart disease |
| WO2000001402A1 (en) | 1998-07-02 | 2000-01-13 | Envision Biomedical Consulting | Antiproliferative and antiviral proteins and peptides |
| US6168785B1 (en) | 1998-07-16 | 2001-01-02 | Institut Pasteur | Biological applications of new peptides of IL-2 and derivatives and use as therapeutic agents |
| AU5300299A (en) | 1998-08-21 | 2000-03-14 | Yeda Research And Development Co. Ltd. | Anti-inflammatory peptides derived from il-2 and analogues thereof |
| CN100480266C (zh) | 1998-10-16 | 2009-04-22 | 拜奥根Idec马萨诸塞公司 | 干扰素-β融合蛋白及用途 |
| US6660843B1 (en) * | 1998-10-23 | 2003-12-09 | Amgen Inc. | Modified peptides as therapeutic agents |
| US7488590B2 (en) | 1998-10-23 | 2009-02-10 | Amgen Inc. | Modified peptides as therapeutic agents |
| HK1042114B (zh) | 1998-10-23 | 2006-09-29 | Amgen K-A, Inc. | 与mp1受体结合并具有血小板生成活性的模拟二聚体血小板生成素肽 |
| AU2880400A (en) | 1999-02-12 | 2000-08-29 | Amgen, Inc. | Tnf-related proteins |
| US6635646B1 (en) | 1999-05-04 | 2003-10-21 | Schering Corporation | Pegylated interferon alfa-CCR5 antagonist combination HIV therapy |
| US6586398B1 (en) | 2000-04-07 | 2003-07-01 | Amgen, Inc. | Chemically modified novel erythropoietin stimulating protein compositions and methods |
| AU5943201A (en) | 2000-05-03 | 2001-11-12 | Amgen Inc | Modified peptides as therapeutic agents |
| US6853809B2 (en) | 2001-01-30 | 2005-02-08 | Koninklijke Philips Electronics N.V. | Camera system for providing instant switching between wide angle and full resolution views of a subject |
| HU229910B1 (hu) | 2001-05-11 | 2014-12-29 | Amgen Inc Thousand Oaks | A TALL-1-hez kötõdõ peptidek és rokon molekulák |
| RU2180233C1 (ru) | 2001-06-26 | 2002-03-10 | Общество с ограниченной ответственностью "Протеиновый контур" | Способ получения жидких лекарственных форм рекомбинантных белков |
| US7332474B2 (en) | 2001-10-11 | 2008-02-19 | Amgen Inc. | Peptides and related compounds having thrombopoietic activity |
| US7138370B2 (en) * | 2001-10-11 | 2006-11-21 | Amgen Inc. | Specific binding agents of human angiopoietin-2 |
| US7205275B2 (en) | 2001-10-11 | 2007-04-17 | Amgen Inc. | Methods of treatment using specific binding agents of human angiopoietin-2 |
| WO2004019860A2 (en) | 2002-08-28 | 2004-03-11 | Pharmacia Corporation | Formulations of modified antibodies and methods of making the same |
| US6919426B2 (en) | 2002-09-19 | 2005-07-19 | Amgen Inc. | Peptides and related molecules that modulate nerve growth factor activity |
| WO2004039337A2 (en) | 2002-10-31 | 2004-05-13 | Protein Design Labs, Inc. | Stable liquid pharmaceutical formulation of antibodies that are prone to isomerization |
| KR20110086881A (ko) | 2002-12-20 | 2011-08-01 | 암겐 인코포레이티드 | 미오스타틴을 저해하는 결합제 |
| CA2572765C (en) | 2004-07-08 | 2013-05-21 | Amgen Inc. | Compound having improved bioefficiency when administered in a multidose regimen |
| US7442778B2 (en) | 2004-09-24 | 2008-10-28 | Amgen Inc. | Modified Fc molecules |
| US9283260B2 (en) * | 2006-04-21 | 2016-03-15 | Amgen Inc. | Lyophilized therapeutic peptibody formulations |
| EP3035305B1 (en) | 2014-12-18 | 2016-11-16 | Axis AB | Enclosure and arrangement for recess mounting of a camera or camera head |
-
2007
- 2007-04-19 US US11/788,697 patent/US9283260B2/en active Active
- 2007-04-19 JO JOP/2007/0154A patent/JO3324B1/ar active
- 2007-04-20 HR HRP20161653TT patent/HRP20161653T1/hr unknown
- 2007-04-20 KR KR1020127022549A patent/KR101236042B1/ko active Active
- 2007-04-20 EP EP12187304.6A patent/EP2594288A1/en not_active Withdrawn
- 2007-04-20 PT PT77759017T patent/PT2018183T/pt unknown
- 2007-04-20 UY UY30302A patent/UY30302A1/es active IP Right Grant
- 2007-04-20 DK DK07775901.7T patent/DK2018183T3/en active
- 2007-04-20 KR KR1020087028391A patent/KR101227278B1/ko active Active
- 2007-04-20 HU HUE07775901A patent/HUE032144T2/en unknown
- 2007-04-20 LT LTEP07775901.7T patent/LT2018183T/lt unknown
- 2007-04-20 SI SI200731856A patent/SI2018183T1/sl unknown
- 2007-04-20 EA EA201270625A patent/EA022424B1/ru not_active IP Right Cessation
- 2007-04-20 EA EA200802170A patent/EA017085B1/ru not_active IP Right Cessation
- 2007-04-20 MY MYPI20084070A patent/MY162816A/en unknown
- 2007-04-20 GE GEAP200710981A patent/GEP20156253B/en unknown
- 2007-04-20 RS RS20161076A patent/RS55428B1/sr unknown
- 2007-04-20 MX MX2008013393A patent/MX2008013393A/es active IP Right Grant
- 2007-04-20 EP EP12187301.2A patent/EP2594286A1/en not_active Withdrawn
- 2007-04-20 BR BRPI0710508A patent/BRPI0710508B8/pt active IP Right Grant
- 2007-04-20 EP EP12187302.0A patent/EP2594287A1/en not_active Withdrawn
- 2007-04-20 UA UAA200813378A patent/UA99815C2/ru unknown
- 2007-04-20 CR CR20170130A patent/CR20170130A/es unknown
- 2007-04-20 AU AU2007240656A patent/AU2007240656A1/en not_active Abandoned
- 2007-04-20 NZ NZ596367A patent/NZ596367A/xx unknown
- 2007-04-20 SG SG10201501296SA patent/SG10201501296SA/en unknown
- 2007-04-20 CN CN201711043851.4A patent/CN107789325A/zh active Pending
- 2007-04-20 WO PCT/US2007/009712 patent/WO2007124090A2/en not_active Ceased
- 2007-04-20 EP EP07775901.7A patent/EP2018183B1/en active Active
- 2007-04-20 ES ES07775901.7T patent/ES2599318T3/es active Active
- 2007-04-20 JP JP2009506615A patent/JP5432705B2/ja active Active
- 2007-04-20 TW TW096114064A patent/TWI352598B/zh active
- 2007-04-20 CA CA2649292A patent/CA2649292C/en active Active
- 2007-04-20 PE PE2007000494A patent/PE20081196A1/es active IP Right Grant
- 2007-04-20 SG SG2011029154A patent/SG182887A1/en unknown
- 2007-04-20 AR ARP070101709A patent/AR060617A1/es not_active Application Discontinuation
- 2007-04-20 EP EP12187298.0A patent/EP2594285B1/en active Active
- 2007-04-20 PL PL07775901T patent/PL2018183T3/pl unknown
- 2007-04-20 CN CNA200780022610XA patent/CN101484185A/zh active Pending
- 2007-04-20 UA UAA201209639A patent/UA116080C2/uk unknown
- 2007-04-20 EP EP12187297.2A patent/EP2594284A1/en not_active Withdrawn
-
2008
- 2008-10-06 ZA ZA200808485A patent/ZA200808485B/xx unknown
- 2008-10-07 TN TNP2008000391A patent/TNSN08391A1/en unknown
- 2008-10-07 IL IL194653A patent/IL194653A/en active IP Right Grant
- 2008-11-14 CR CR10442A patent/CR10442A/es unknown
- 2008-11-20 MA MA31391A patent/MA30474B1/fr unknown
- 2008-11-20 NO NO20084893A patent/NO344947B1/no unknown
-
2013
- 2013-02-27 IL IL224966A patent/IL224966A/en active IP Right Grant
- 2013-09-27 JP JP2013201931A patent/JP5873854B2/ja active Active
-
2014
- 2014-06-12 CR CR20140274A patent/CR20140274A/es unknown
- 2014-12-23 PH PH12014502880A patent/PH12014502880A1/en unknown
-
2015
- 2015-10-22 JP JP2015208065A patent/JP6356106B2/ja active Active
-
2016
- 2016-01-29 US US15/011,229 patent/US10166189B2/en active Active
- 2016-09-20 CY CY20161100932T patent/CY1118038T1/el unknown
- 2016-09-29 IL IL248156A patent/IL248156B/en active IP Right Grant
-
2018
- 2018-06-12 JP JP2018111720A patent/JP6787953B2/ja active Active
-
2020
- 2020-07-30 JP JP2020128961A patent/JP2021006525A/ja active Pending
-
2022
- 2022-08-18 JP JP2022130437A patent/JP2022166219A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016065060A5 (enExample) | ||
| US10905739B2 (en) | Peptidomimetic macrocycles and formulations thereof | |
| HRP20161653T1 (hr) | Liofilizirane formulacije terapeutskih peptitijela | |
| JP2009540001A5 (enExample) | ||
| JP2016516062A5 (enExample) | ||
| JP2020063241A5 (enExample) | ||
| JP2009524595A5 (enExample) | ||
| KR20140082649A (ko) | 프로스타사이클린의 서방형 조성물 | |
| FI4206216T3 (fi) | Adenoassosioituneen viruksen kapsidimuunnoksia ja menetelmiä niiden käyttämiseksi | |
| JP2011519833A5 (enExample) | ||
| JP2013525414A5 (enExample) | ||
| RU2010114015A (ru) | Применение пептида в качестве терапевтического средства | |
| JP2020169191A5 (enExample) | ||
| RU2010114021A (ru) | Субстанция р и тиролиберин для терапевтического применения | |
| JP2012136518A5 (enExample) | ||
| JP2016520075A5 (enExample) | ||
| JP2019509311A5 (enExample) | ||
| CN112055588B (zh) | 卡巴他赛的制剂和组合物 | |
| US11654178B2 (en) | Cyclic prosaposin peptides and uses thereof | |
| JP2017510585A5 (enExample) | ||
| WO2022192450A3 (en) | Self-assembling peptides, nanofibers, and methods of use | |
| JP2025087701A (ja) | π電子対供与複素環式芳香族窒素含有化合物のコンジュゲート | |
| JP2016520646A (ja) | Ｇｃ−マクロファージ活性化因子を含む組成物およびその使用 | |
| EP3169348B1 (en) | Pharmaceutical compositions comprising agonists of orexin-1 receptor ox1r for the treatment of inflammatory bowel diseases | |
| ES2864667T3 (es) | Péptidos diseñados para la modulación de la barrera de unión estrecha |